
Opinion|Videos|February 27, 2025
Initial Treatment Options for Liver-Confined Unresectable HCC
Author(s)Amit Singal, MD
The panelist discusses first-line options including atezolizumab plus bevacizumab, lenvatinib, and sorafenib. Second-line treatments include regorafenib, cabozantinib, and ramucirumab. Clinical trials should be prioritized when available.
Advertisement
Video content above is prompted by the following:
- Please briefly review the treatment options for patients with hepatocellular carcinoma (HCC) confined to the liver but unresectable according to NCCN guidelines.
- Please discuss standard treatment modalities and share your impressions on the initial treatment approach in this case.
Advertisement
Related to this article

During a live event, Robert Orlowski, MD, PhD, and participants discussed selinexor combinations, dosing, and nausea prevention for an older patient with late relapsed multiple myeloma who declines CAR T.

Sac-TMT improved OS vs physician’s choice in pretreated gastroesophageal adenocarcinoma in the phase 3 TroFuse-015 trial; PFS was not improved.

Updated RMC-GI-102 data show 60.7% ORR and 12.8-month median PFS with daraxonrasib plus GnP in first-line metastatic PDAC.

Modern Hodgkin lymphoma treatment is tied to a 25% drop in solid second cancers, but breast and lung cancer risks persist for decades.

ESMO data show the phase 3 INTerpath-001 trial of intismeran autogene plus pembrolizumab improved recurrence-free survival in resected stage IIB to IV melanoma.

In HypoMast-IMNI, 16-fraction radiotherapy was noninferior to 25 fractions for locoregional recurrence after mastectomy in high-risk breast cancer.

Five-year PHERGain results support PET-guided treatment de-escalation in HER2-positive breast cancer, with ctDNA offering insight into recurrence risk
Advertisement
Advertisement
Trending on Targeted Onc
1
Daraxonrasib Plus Chemo Yields Durable Response in First-Line PDAC
2
PET-Guided Strategy May Spare Chemotherapy in HER2-Positive Breast Cancer
3
Treatment Sequencing and Toxicity Are Top Concerns in HER2-Mutant NSCLC
4
Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML
5

